Save Product
Product Details
Product Overview
Human Erythropoietin (EPO) ELISA Kit, PRO is a ready-to-use immunoassay kit, specifically designed to quantitate natural and recombinant human EPO that is present in biological samples, such as human serum, plasma, and cell culture supernatants. Our ELISA Kit provides several benefits:
- Standards to calibrate with NIBSC/WHO standards for comparable results.
- Fully validation in biologic samples for detection range, sensitivity, inter- and intra-plate CV, recovery, dilution linearity, specificity, and matrix effects to ensure reliable results according to ICH M10 guideline.
- High-quality antibody pairs and protein standards, along with rigorous quality control, to guarantee consistent results across different batches.
- Simplified and straightforward protocols and ready-to-use reagents to save assay time.
Product Specifications
Assay TypeSandwich-ELISAAnalyteEPOFormat96-wells plate breakable into 12 x 8 wells stripsReactivityHumanSensitivity0.67 mlU/mLAssay Time2 hr 45 minSample volume50 μLRange0.87 mlU/mL-212 mlU/mLSample TypeCell Culture Supernatants, Plasma, Serum.NIBSC Code11/170Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
Application
The kit is developed for quantitative detection of natural and recombinant human EPO in serum, plasma and cell culture supernatants.
It is for research use only.
Workflow
Storage
Keep the unopened kit stored at 2-8 °C. Avoid using the kit beyond its expiration date. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
Materials Provided
IDComponentsSizeCEA027-C01Pre-coated Anti-EPO Antibody Microplate1 plateCEA027-C02Human EPO Standard3392 IU×2CEA027-C03Biotin-Anti-EPO Antibody Con. Solution100 μLCEA027-C04Biotin-Antibody Dilution Buffer8 mLCEA027-C05Streptavidin-HRP Con. Solution500 μLCEA027-C06HRP Dilution Buffer15 mLCEA027-C0720×Washing Buffer50 mLCEA027-C08Sample Dilution Buffer15 mL×2CEA027-C09Substrate Solution12 mLCEA027-C10Stop Solution6 mLACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
For each experiment, each ELISA plate needs to set the standard curve. The minimum detectable concentration of EPO is less than 0.67 mIU/mL.
Sample Values
Serum Sample: Forty healthy serum samples and fourteen patient serum samples were evaluated for the concentrations of human EPO in assay.
Precision
To evaluate the intra-assay precision of assay using CEA-C027 and Competitor R, four samples spiked with different concentrations of EPO were tested. Results shown in the following Table. CV values of all analytes are less than 6%. Acceptable criteria : CV<10%.
Matrix Effect
To evaluate the hemolysis matrix effect and high-dose triglyceride matrix effect of assay, serum samples spiked with high concentrations of hemoglobin (2%), or triglyceride (3 mg/mL) were tested. Results shown that all spiked analytes had recoveries between 90% and 110%, no hemolysis matrix effect and high-dose triglyceride matrix effect was observed in assay using CEA-C027.
Hook Effect
To evaluate the hook effect of the assay, some samples with high concentration of EPO were tested. Results shown in the following figure. No hook effect was found in the assay using the CEA-C027.
Dilution Linearity
To evaluate the linearity of assay using CEA-C027 and Competitor R, samples (Serum, EDTA plasma) spiked with high concentrations of EPO were serially diluted with dilution buffer to produce samples with values within the dynamic range of the assay. Results shown that recoveries of all analytes are less than 120%. Acceptable criteria: Recovery should be between 80% and 120%.
Recovery
To evaluate the recovery of assay using CEA-C027 and Competitor R, samples (Serum, EDTA plasma) spiked with low concentrations of EPO (LQC) were tested. All analytes had recoveries between 80% and 100%. Acceptable criteria: Recovery should be between 80% and 120%.
Consistency
To evaluate the consistency of assay using CEA-C027 and Competitor R, forty healthy serum samples and fourteen patient serum samples were tested, and these results demonstrated a high degree of consistency between the two products, R² >0.95.
Customer Reviews Writing Reviews
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing